Published in Med Clin (Barc) on November 11, 2009
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Effectiveness of blood pressure control outside the medical setting. Hypertension (2006) 4.38
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) (2012) 2.03
[Use of antihypertensive drug therapy and risk of development of congestive heart failure]. Med Clin (Barc) (2004) 2.03
Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry. J Hypertens (2014) 1.97
Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry. J Hypertens (2007) 1.62
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens (2011) 1.57
Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. Hypertens Res (2011) 1.52
Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. Hypertension (2011) 1.47
[Prevalence of target organ damage and metabolic abnormalities in resistant hypertension]. Med Clin (Barc) (2011) 1.42
Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study. Eur Heart J (2013) 1.37
Cerebral hemodynamics and silent cerebral white matter lesions in middle-aged essential hypertensive patients. Blood Press (2004) 0.98
Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens (2014) 0.96
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol (2004) 0.94
Salt intake, endothelial dysfunction, and salt-sensitive hypertension. J Clin Hypertens (Greenwich) (2002) 0.92
Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis (2013) 0.91
Early detection and management of the high-risk patient with elevated blood pressure. Vasc Health Risk Manag (2008) 0.90
'Multiple action fixed combination. Present or future?'. Fundam Clin Pharmacol (2009) 0.88
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press (2007) 0.86
Association of the G protein beta3 subunit T allele with insulin resistance in essential hypertension. Clin Exp Hypertens (2002) 0.86
Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther (2003) 0.86
Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance. J Hypertens (2013) 0.85
Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens (2014) 0.85
Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv Ther (2014) 0.84
Renin-angiotensin system genetic polymorphisms and cerebral white matter lesions in essential hypertension. Hypertension (2002) 0.84
Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. J Hypertens (2014) 0.84
Correlation between silent cerebral white matter lesions and left ventricular mass and geometry in essential hypertension. Am J Hypertens (2002) 0.83
Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens (2016) 0.83
Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol Hypertens (2005) 0.83
ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. High Blood Press Cardiovasc Prev (2014) 0.82
AT1 blockers and uric acid metabolism: are there relevant differences? J Hypertens Suppl (2002) 0.82
Clinical characteristics of isolated clinic hypertension. J Hypertens (2008) 0.82
[Factors predicting a short length of stay for acute exacerbations of chronic obstructive pulmonary disease]. Med Clin (Barc) (2005) 0.82
Target organ damage: how to detect it and how to treat it? J Hypertens Suppl (2009) 0.82
The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. Am J Cardiovasc Drugs (2009) 0.81
Magnitude of the white-coat effect in the community pharmacy setting: the MEPAFAR study. Am J Hypertens (2011) 0.81
Undiagnosed obesity in hypertension: clinical and therapeutic implications. Blood Press (2007) 0.80
Gender differences in office and ambulatory control of hypertension. Am J Med (2008) 0.80
Should hypertension guidelines be changed for hypertensive patients with the metabolic syndrome? J Clin Hypertens (Greenwich) (2007) 0.80
Prevalence of renal insufficiency in individuals with hypertension and obesity/overweight: the FATH study. J Am Soc Nephrol (2006) 0.79
Combination therapy in hypertension. Adv Ther (2013) 0.78
Blood pressure control in the hypertensive population. What else the doctor can do? J Hypertens (2010) 0.78
[Ambulatory blood pressure monitoring (CABPM): clinical characteristics of 31,530 patients]. Med Clin (Barc) (2007) 0.77
Definition of white coat hypertension: ambulatory blood pressure, self-measured blood pressure, or both? Hypertension (2013) 0.77
Prognostic impact of sex-ambulatory blood pressure interactions in 10 cohorts of 17 312 patients diagnosed with hypertension: systematic review and meta-analysis. J Hypertens (2015) 0.77
Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. J Clin Hypertens (Greenwich) (2014) 0.76
Antihypertensive therapy in patients with metabolic syndrome. Curr Opin Nephrol Hypertens (2006) 0.76
Putative endothelial progenitor cells are associated with flow-mediated dilation in refractory hypertensives. Blood Press (2008) 0.76
Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. J Cardiovasc Pharmacol (2002) 0.76
Relation of left ventricular hypertrophy to regional cerebral blood flow: single photon emission computed tomography abnormalities in essential hypertension. J Clin Hypertens (Greenwich) (2006) 0.76
Validation of a therapeutic scheme for the treatment of resistant hypertension. J Am Soc Hypertens (2011) 0.76
[Management of hypertension in the very old]. Med Clin (Barc) (2011) 0.75
One step forward for serelaxin as a promising therapy in cardiac fibrosis. Hypertension (2014) 0.75
Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. Am J Hypertens (2002) 0.75
Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Curr Med Res Opin (2007) 0.75
Relationship between urinary albumin excretion and blood pressure in the community pharmacy: the Palmera study. Am J Hypertens (2013) 0.75
Difficult-to-control hypertension: effects of olmesartan-based combination therapies. J Hypertens (2013) 0.75
A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide. Vasc Health Risk Manag (2013) 0.75
24-h pulse pressure cutoff point definition by office pulse pressure in a population of Spanish older hypertensive patients. J Hypertens (2017) 0.75
[Prognostic value of high blood pressure in diabetic patients]. Med Clin (Barc) (2007) 0.75
[Effectiveness of antihypertensive treatment and control of blood pressure: is it improvable?]. Med Clin (Barc) (2013) 0.75
[Recent evidence of support to arterial hypertension treatment guides]. Med Clin (Barc) (2008) 0.75
Detection and treatment of resistant hypertension. Curr Hypertens Rep (2010) 0.75
[Prevalence of target organ damage and factors associated with cardiovascular events in subjects with refractory hypertension]. Med Clin (Barc) (2009) 0.75
Urinary albumin excretion at follow-up predicts cardiovascular outcomes in subjects with resistant hypertension. Am J Hypertens (2013) 0.75
Isolated clinic hypertension: diagnostic criteria based on 24-h blood pressure definition. J Hypertens (2010) 0.75
[Selective inhibitors of cyclooxigenase-2 (Coxibs) and cardiovascular morbidity]. Med Clin (Barc) (2002) 0.75
Blood pressure as a therapeutic target in stroke. Curr Top Med Chem (2009) 0.75
[Accuracy of the automated oscillometric device Lohmeier B-606, for blood pressure measurement in hospitals]. Med Clin (Barc) (2002) 0.75
Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents? Ther Adv Cardiovasc Dis (2009) 0.75
The International Cardiovascular and Metabolic Academy Symposium. Foreword. J Hypertens Suppl (2009) 0.75
[Effectiveness and safety of calcium antagonists in hypertensive patients]. Med Clin (Barc) (2005) 0.75
[Pulse pressure and cardiovascular risk: from epidemiology to pathophysiology]. Med Clin (Barc) (2008) 0.75
[New targets in patients with cardiometabolic risk]. Med Clin (Barc) (2007) 0.75
[Stratification and degree of control of cardiovascular risk factors in hypertensive Spanish population. Results of the DICOPRESS study]. Med Clin (Barc) (2007) 0.75
[Lack of association between blood pressure variability and left ventricular hypertrophy in essential hypertension]. Med Clin (Barc) (2004) 0.75
[Effectiveness of an educational intervention on hypertension directed at elderly hypertensive patients]. Rev Esp Geriatr Gerontol (2012) 0.75
Usefulness of blood pressure measurement by community pharmacists in the management of hypertension. J Manag Care Pharm (2012) 0.75
Management of cardiovascular risk factors in patients with metabolic syndrome. Cardiovasc Hematol Agents Med Chem (2007) 0.75
[Relevance of diabetes in high cardiovascular risk hypertensive patients]. Med Clin (Barc) (2012) 0.75
[Renal function protection in type 2 diabetic patients]. Med Clin (Barc) (2002) 0.75
Identifying masked uncontrolled hypertension in the community pharmacy setting. Blood Press Monit (2015) 0.75
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy. Expert Opin Pharmacother (2005) 0.75